Beset by challenges with its Alzheimer’s disease drug, Biogen pivots
May 03, 2022 at 12:47 PM EDT
The company plans to let go of its CEO and scrap commercial plans for its controversial Alzheimer’s disease drug.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|